Xenon Pharmaceuticals Inc (XENE)

Price$53.41

Value ScoreF

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)19.98%

Price vs S&P 500 (4W)-7.47%

VGM Score33.07

Market Capitalization$5.29B

All Metrics

Book Value / Share (Quarterly)$13.85

P/TBV (Annual)2.63x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-7.35%

Cash Flow / Share (Quarterly)$-3.18

Price vs S&P 500 (YTD)11.18%

Net Profit Margin (TTM)-867.29%

EPS (TTM)$-4.70

10-Day Avg Trading Volume1.32M

EPS Excl Extra (TTM)$-4.70

Revenue Growth (5Y)-25.27%

EPS (Annual)$-4.36

ROI (Annual)-59.46%

Net Profit Margin (5Y Avg)-1413.62%

Cash / Share (Quarterly)$11.33

ROA (Last FY)-54.63%

EBITD / Share (TTM)$-5.04

ROE (5Y Avg)-28.38%

Operating Margin (TTM)-969.84%

Cash Flow / Share (Annual)$-3.50

P/B Ratio3.95x

P/B Ratio (Quarterly)4.01x

Net Income / Employee (Annual)$-966,200

EV / Revenue (TTM)632.62x

Net Interest Coverage (TTM)-38.23x

ROA (TTM)-46.41%

EPS Incl Extra (Annual)$-4.36

Current Ratio (Annual)13.42x

Quick Ratio (Quarterly)27.53x

3-Month Avg Trading Volume1.28M

52-Week Price Return88.46%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.79

P/S Ratio (Annual)705.40x

Asset Turnover (Annual)0.01x

52-Week High$63.95

Operating Margin (5Y Avg)-1499.88%

EPS Excl Extra (Annual)$-4.36

CapEx CAGR (5Y)-21.26%

Tangible BV CAGR (5Y)82.20%

26-Week Price Return35.91%

Quick Ratio (Annual)13.17x

13-Week Price Return21.84%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)27.79x

Enterprise Value$4.74B

Revenue / Share Growth (5Y)-36.71%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)8.23%

Revenue / Employee (Annual)$20,900

Pretax Margin (Annual)-4598.59%

Cash / Share (Annual)$6.86

3-Month Return Std Dev102.79%

Net Income / Employee (TTM)$-1,070,300

ROE (Last FY)-59.46%

Net Interest Coverage (Annual)-22.77x

EPS Basic Excl Extra (Annual)$-4.36

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.70

Receivables Turnover (Annual)5.28x

ROI (TTM)-49.23%

P/S Ratio (TTM)705.40x

Pretax Margin (5Y Avg)-1410.90%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$11.53

Price vs S&P 500 (52W)60.26%

Year-to-Date Return22.11%

5-Day Price Return1.03%

EPS Normalized (Annual)$-4.36

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-4612.13%

Month-to-Date Return-2.34%

Cash Flow / Share (TTM)$-2.61

EBITD / Share (Annual)$-4.68

Operating Margin (Annual)-4974.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.38%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.70

P/TBV (Quarterly)2.98x

P/B Ratio (Annual)6.09x

Pretax Margin (TTM)-861.60%

Book Value / Share (Annual)$7.27

Price vs S&P 500 (13W)12.09%

Beta0.63x

P/FCF (Annual)117.46x

Revenue / Share (TTM)$0.00

ROE (TTM)-49.23%

52-Week Low$28.19

vGradeF

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.17est. -1.21

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.35

4.37

4.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XENEXenon Pharmaceuticals Inc	F	F	B	$53.41
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Xenon Pharmaceuticals is a biopharmaceutical company developing novel treatments for neurological and psychiatric disorders, including epilepsy, depression, and pain. The company's pipeline includes three epilepsy candidates—XEN1101, NBI-921352, and XEN496—as well as oral Nav1.7 inhibitors for pain management. It targets areas with significant unmet medical need in neuroscience.